IGF1 and autoimmune disease: Here, we define the Treg cell as a direct target of IGF-1 action in both mouse and human and demonstrate the more general ability of IGF-1 to control pathological responses in mouse models of autoimmune disease, using a clinically relevant continuous delivery protocol based on intensive systemic recombinant human IGF-1 release.